Medulloblastoma: Molecular Classification-Based Personal Therapeutics

摘要

Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas, each with unique transcription profiles, DNA alterations and clinical outcome. Molecular classification of medulloblastomas improves predictions of clinical outcome, allowing more accurate matching of intensity of conventional treatments with chemotherapy and radiation to overall prognosis and setting the stage for the introduction of targeted therapies.Electronic supplementary materialThe online version of this article (doi:10.1007/s13311-017-0526-y) contains supplementary material, which is available to authorized users.